香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本次獲批將進一步有助於本公司鞏固於抗感染領域的優勢地位。本公司將持續致力於 新產品研發，預期將為本公司及其股東創造更大收益。 承董事會命 聯邦制藥國際控股有限公司 主席 蔡海山 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 ( 於開曼群島成立之有限公司 ) (股份代號: 3933) 本集團產品羅紅霉素膠囊通過一致性評價 本公告乃由聯邦制藥國際控股有限公司（「本公司」）自願發出。 本公司董事會（「董事會」）欣然公佈，本公司全資附屬公司珠海聯邦制藥股份有限公 司中山分公司申報的羅紅霉素膠囊（規格：150mg）通過中國國家藥品監督管理局仿 製藥質量和療效一致性評價（「一致性評價」）。 羅紅霉素膠囊是第二代大環內酯類抗生素，具有耐酸性好、抗菌譜廣、組織穿透性強、 不良反應發生率較低等顯著抗感染優勢。臨床適用於治療由羅紅霉素 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [3] Core Insights - The commercialization of ADC (Antibody-Drug Conjugates) is accelerating, with 20 ADC drugs approved globally, and 6 of them have been in the "billion-dollar club" for two consecutive years [30][31] - The report highlights the increasing competition in the ADC sector, with approximately 60 ADC drugs currently in clinical phase 3 and application stages [30] - Domestic innovative pharmaceutical companies are adopting various strategies for ADC capacity layout, with companies like Rongchang Biopharma transitioning from outsourcing to in-house production, while others like Kelong Biotechnology are building their own production bases [31][32] Summary by Sections Market Review - The pharmaceutical index rose by 0.14% this week, outperforming the CSI 300 index by 1.47 percentage points, ranking 15th in industry performance [10] - Year-to-date, the pharmaceutical index has increased by 3.28%, also outperforming the CSI 300 index by 2.99 percentage points, ranking 23rd [10] Individual Stock Performance - In the A-share market, 255 out of 479 pharmaceutical stocks rose, with the top five performers being Guangshengtang (+29.83%), Haixiang Pharmaceutical (+18.64%), and Meidixi (+18.04%) [20] - In the Hong Kong market, 38 out of 116 pharmaceutical stocks rose, with the top performers including Yiteng Jiahe (+14%) and Kedi-B (+9.96%) [24] Industry News and Policies - The newly revised "Regulations on the Implementation of the Drug Administration Law" supports segmented contract manufacturing and commercial-scale drug sales, providing a foundation for ADC commercialization cooperation [32] - Notable industry developments include Novartis's application for Ianalumab in China and Johnson & Johnson's approval of Daratumumab injection for multiple myeloma treatment [27][28] Weekly Insights - The ADC commercialization battle has begun, with a significant increase in demand for ADC production capacity, leading to a supply-demand imbalance [30] - Major CXO companies are expanding ADC production capacity, with companies like WuXi AppTec acquiring East Yao Pharmaceutical to meet rising orders [31]

Core Viewpoint - The "Zhuhai Intelligent Manufacturing (Hong Kong-Zhuhai-Macao Bridge Special Session)" event aims to leverage the bridge's connectivity to promote Zhuhai and Guangdong's quality products to global markets, enhancing cross-border e-commerce opportunities [2][3]. Group 1: Event Overview - The event featured live streaming and an exhibition area showcasing Zhuhai's intelligent manufacturing products alongside Hong Kong and Macao quality goods, facilitating easier access to international markets [2][5]. - Gree Electric's chairman promoted their smart home appliances during the live broadcast, attracting significant online engagement [3][5]. Group 2: Product Showcase - The exhibition displayed a variety of products, including air purifiers, laser printers, Hi-Fi audio systems, and health foods, appealing to attendees from Hong Kong and Macao [5][7]. - A notable product highlighted was a pet product that offers competitive pricing domestically while having a premium in overseas markets, exemplifying the potential of Chinese goods abroad [8]. Group 3: Cross-Border E-commerce Development - The Huafa Hengqin Cross-Border E-commerce Industrial Park has nearly 200 enterprises, including 27 listed companies, with e-commerce-related firms making up about 70% of the total [8]. - The park aims to support businesses in navigating international regulations and enhancing their export capabilities through shared resources and training [8]. Group 4: Economic Impact and Projections - By 2025, the import and export value through the bridge is projected to exceed 325.84 billion yuan, marking a 40.1% increase year-on-year, with cross-border e-commerce exports expected to reach 110.98 billion yuan, a 92.5% increase [11][12]. - The bridge has significantly improved logistics efficiency, with measures in place to streamline customs processes, enhancing the overall trade environment [12]. Group 5: Future Initiatives - Zhuhai plans to host numerous offline matchmaking events and continuous online promotional activities to further facilitate the global reach of its products [12].

研究报告 Research Report 9 Feb 2026 香港医疗 Hong Kong Health Care 医药行业周报（2026.02.02-2026.02.06）：市场情绪回暖；看好基本面表现强劲的创新药产业链龙头 Healthcare Weekly (2026.02.02-2026.02.06): Market Sentiment Warms; Bullish on Leaders in Innovative Drug Chain with Strong Fundamentals [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | 评级 | | 百济神州 | Outperform 华润医药 | | Outperform | | 京东健康 | Outperform 国药控股 | | Neutral | | 药明生物 | Outperform 映恩生物 | | Outperform | | 信达生物 | Outperform 金斯瑞生物科 ...

Market Overview - US stock indices fell across the board, with December JOLTS job openings hitting a five-year low, significantly below expectations [1] - Challenger companies announced 108,000 layoffs in January, the highest for the same period since 2009, with a month-on-month increase of 205% [1] - Initial jobless claims rose to 231,000, an increase of 22,000 from the previous week, exceeding expectations, indicating a deteriorating economic situation [1] - Hong Kong stocks were also affected, closing down 1.21% [1] Technology Impact - The decline in job openings is partly attributed to advancements in artificial intelligence, such as Anthropic's Claude Opus 4.6, which outperforms GPT-5.2 in various fields [1] - Financial data service providers like FactSet experienced a significant drop of 10% in stock price, with S&P Global, Moody's, and Nasdaq also declining [1] Automotive Sector - NIO (09866) forecasted adjusted operating profit for Q4 2025 between RMB 700 million (approximately $100 million) and RMB 1.2 billion (approximately $172 million), driven by sales growth and improved product mix [3] - Li Auto (02015) is preparing to launch the new Li L9, featuring advanced technology and a price of RMB 559,800, with a market focus on high-end segments [3] - Both NIO and Li Auto showed positive stock performance, with NIO rising nearly 7% and Li Auto increasing by nearly 4% [3] Consumer Goods - The upcoming Spring Festival is boosting sales in the snack sector, with major companies ramping up production to meet demand [4] - Zhongtong Express (02057) projected total revenue for 2025 between RMB 48.5 billion and RMB 50 billion, a growth of approximately 9.5% to 12.9% from 2024 [4] - SF Express (09699) expects a profit of no less than RMB 238 million for 2025, with a year-on-year increase of over 80% [4] Dairy Industry - Dairy prices are at a low point, with a reduction in dairy cow inventory and losses in farms leading to the exit of inefficient production capacity [5] - The price of milk is expected to stabilize and rise by 2026, benefiting upstream farms and downstream dairy companies [5] - Yurun Dairy (09858) and Mengniu Dairy (02319) saw stock increases of over 4% and 3%, respectively [5] Pharmaceutical Sector - Innovent Biologics (09969) announced a positive earnings forecast, expecting revenue of RMB 2.37 billion for 2025, a year-on-year increase of approximately 134% [6] - The company anticipates its first profitable year with a net profit of around RMB 630 million [6] - Federal Pharmaceutical (03933) received approval for a new drug, enhancing its position in the market [6] Oil Market - Reports indicate that Russia has increased discounts on oil exports to China, aiming to attract demand amid declining purchases from India [7] - If India reduces its imports, China may become the primary buyer of discounted Russian oil, benefiting oil refining companies [7] - Major companies in the Hong Kong market include Sinopec (00386) and Shanghai Petrochemical (00338) [7] Duty-Free Market - China Duty Free Group (01880) reported a nearly 20% year-on-year increase in shopping totals at duty-free stores in Hainan since the new policy implementation [8] - The company holds a significant market share in Hainan's duty-free sector, with a strong supply chain and partnerships with over 1,000 luxury brands [9] - The expansion of duty-free shopping in Hainan is expected to enhance the company's growth prospects [9]

Group 1: Market Overview - The Hong Kong pharmaceutical sector showed significant recovery on February 6, with innovative drugs experiencing a rebound, particularly the Hong Kong Stock Connect Innovative Drug ETF (520880), which rose by nearly 2% after opening in the red [1] - Notable stocks included Nocera Biopharma, which surged over 12%, projecting revenues of 2.37 billion yuan for 2025, a year-on-year increase of approximately 134%, and an expected net profit of around 630 million yuan, marking its first profit [1] Group 2: Company Performance - Rongchang Biopharma and CanSino Biologics also reported profitability, with both companies forecasting net profit growth exceeding 100% year-on-year [1] - Ark Health announced a profit forecast of 7 to 10 million yuan for 2025, indicating a turnaround from losses, and raised approximately 144.3 million HKD to accelerate the development of its AI-driven chronic disease management platform [3] - Among the 10 component stocks of the Hong Kong Stock Connect Medical ETF (159137) that disclosed earnings forecasts, 9 are expected to report profits, with several companies like Zhaoyan New Drug, MicroPort Medical, and WuXi AppTec anticipating net profit growth of over 100% [3]

Group 1 - The stock of United Pharmaceuticals (03933.HK) has increased by over 7%, currently up by 6.1% at HKD 13.39 [1] - The trading volume reached HKD 80.98 million [1]

Core Viewpoint - Federal Pharmaceutical (03933) has seen a significant stock increase, attributed to the announcement of its innovative drug UBT251 receiving clinical trial approval for obesity-related moderate to severe obstructive sleep apnea (OSA) from the National Medical Products Administration of China [1] Group 1: Company Developments - Federal Pharmaceutical's wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has developed UBT251, which is the first chemical-synthetic GLP-1/GIP/GCG tri-target receptor agonist new drug in China [1] - The company has established a strong position in the research field of this type of medication, enhancing its competitive edge [1] Group 2: Financial Insights - UBS has released a report stating that Federal Pharmaceutical is a leading drug manufacturer in China, with an integrated business line covering intermediate products, active pharmaceutical ingredients, and formulation products [1] - The company has a strong research and development background in metabolic diseases, which has led to promising early clinical results for UBT251 [1] - In March of the previous year, the company licensed the rights for UBT251 outside of China to Novo Nordisk (NVO.US), which included a $200 million upfront payment, up to $1.8 billion in milestone payments, and tiered royalties on sales [1] Group 3: Market Potential - UBS believes that the market has underestimated the sales potential of UBT251 and the broader innovative research and development pipeline of the company [1]

Core Viewpoint - Federal Pharmaceutical (03933) has seen a significant stock increase of over 7%, currently trading at HKD 13.39, with a transaction volume of HKD 80.98 million, following the announcement of its innovative drug UBT251 receiving clinical trial approval for obesity-related moderate to severe obstructive sleep apnea (OSA) from the National Medical Products Administration of China [1] Group 1: Company Developments - Federal Pharmaceutical's wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has independently developed the innovative drug UBT251 injection, marking it as China's first chemical-synthesized GLP-1/GIP/GCG tri-target receptor agonist [1] - The company has established a significant position in the research field of this type of medication, enhancing its competitive edge in the pharmaceutical industry [1] Group 2: Market Analysis - UBS has released a report stating that Federal Pharmaceutical is a leading drug manufacturer in China, with an integrated business line that includes intermediate products, active pharmaceutical ingredients, and formulation products [1] - The report highlights that the market may be underestimating the sales potential of UBT251 and the broader innovative research pipeline of the company [1] - Last year, the company licensed the rights of UBT251 outside of China to Novo Nordisk (NVO.US), which included an upfront payment of USD 200 million, potential milestone payments of up to USD 1.8 billion, and tiered royalties on sales [1]

Core Viewpoint - The penicillin industry in China is undergoing structural adjustment and high-quality development, with a complete industrial chain from raw material supply to end application, and is expected to maintain steady growth driven by increasing demand from grassroots healthcare and an aging population [1][12]. Industry Overview - Penicillin is a β-lactam antibiotic that disrupts bacterial cell walls and is crucial in treating bacterial infections, significantly impacting human health since its discovery [1][12]. - The Chinese penicillin industry has established a mature industrial chain and occupies a significant position in the global intermediate market [1][12]. - The market size of the Chinese penicillin industry is projected to reach 28.243 billion yuan in 2024, with a year-on-year growth of 4.45% [1][12]. Industry Development History - Penicillin was the first broad-spectrum antibiotic discovered, significantly increasing human lifespan and saving millions during World War II [7]. - China began domestic production of penicillin in the early 1950s, achieving self-sufficiency and eventually becoming the world's largest producer by 2001 [7]. Industry Chain - The penicillin industry chain consists of upstream raw material suppliers and strain research institutions, midstream penicillin producers and intermediate manufacturers, and downstream sales channels including pharmaceutical distributors and e-commerce platforms [8][10]. Current Industry Status - The antibiotic industry in China is primarily focused on generic drug production, with limited innovative drug development [10][11]. - The market size of the antibiotic industry is expected to grow from 153.384 billion yuan in 2016 to 217.251 billion yuan in 2024, with a compound annual growth rate of 4.45% [10][11]. Competitive Landscape - The Chinese penicillin industry features a mix of domestic and foreign companies, with domestic firms like North China Pharmaceutical and Shijiazhuang Pharmaceutical Group gradually replacing foreign products in the mid to low-end market [13][14]. Key Companies - North China Pharmaceutical Co., Ltd. is a leading player in the antibiotic sector, with a comprehensive product line covering raw materials to formulations, and reported a revenue of 2.251 billion yuan in chemical preparations for the first half of 2025, a decrease of 6.36% year-on-year [15][16]. - Shandong Lukang Pharmaceutical Co., Ltd. focuses on a diverse range of pharmaceutical products and reported a revenue of 3.384 billion yuan for human medicines in 2024, reflecting a growth of 5.16% [16]. Industry Development Trends - Future research and development in penicillin will focus on innovative drug design to combat antibiotic resistance and enhance clinical efficacy [17]. - Clinical applications of penicillin are shifting towards precision medicine, utilizing advanced diagnostic techniques for optimal drug selection [18]. - Production processes are expected to transition to more efficient and environmentally friendly methods, enhancing productivity and reducing waste [20]. - Quality standards in the penicillin industry will evolve to encompass comprehensive lifecycle management, ensuring high safety and efficacy [21].